Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners